The estimated Net Worth of Amy W Schulman is at least $6.98 Million dollars as of 25 June 2024. Ms. Schulman owns over 8,500 units of Alnylam Pharmaceuticals Inc stock worth over $4,435,708 and over the last 12 years she sold ALNY stock worth over $2,055,200. In addition, she makes $485,707 as Independent Director at Alnylam Pharmaceuticals Inc.
Amy has made over 10 trades of the Alnylam Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently she exercised 8,500 units of ALNY stock worth $1,115,285 on 25 June 2024.
The largest trade she's ever made was buying 626,117 units of Alnylam Pharmaceuticals Inc stock on 8 April 2019 worth over $10,017,872. On average, Amy trades about 17,462 units every 66 days since 2012. As of 25 June 2024 she still owns at least 16,936 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Ms. Schulman stock trades at the bottom of the page.
Amy W. Schulman is Independent Director of the Alnylam Pharmaceuticals, Inc. Ms. Schulman joined Polaris Partners, a venture capital firm, in August 2014. In July 2015, Ms. Schulman co-founded Lyndra, Inc., where she serves as the Chief Executive Officer and a director. In February 2017, Ms. Schulman became Chief Executive Officer of Olivo Laboratories, LLC and also serves as Executive Chair of SQZ Biotech. Since July 2014, Ms. Schulman has also been a senior lecturer at Harvard Business School. Ms. Schulman served as Chief Executive Officer of Arsia Therapeutics, Inc. from August 2014 to November 2016, when Arsia was acquired by Eagle Pharmaceuticals, Inc. Ms. Schulman was previously the Executive Vice President and General Counsel of Pfizer Inc., a global pharmaceutical company, from May 2008 to July 2014, where she also served as the Business Unit Lead for Pfizer’s Consumer Healthcare business from 2012 to 2013. Before joining Pfizer, she was a partner at DLA Piper. Ms. Schulman also serves as a director of Ironwood Pharmaceuticals, Inc. and Arsanis, Inc., and formerly served as a director of Blue Buffalo Pet Products, Inc. and BIND Therapeutics, Inc.
As the Independent Director of Alnylam Pharmaceuticals Inc, the total compensation of Amy Schulman at Alnylam Pharmaceuticals Inc is $485,707. There are 15 executives at Alnylam Pharmaceuticals Inc getting paid more, with John Maraganore having the highest compensation of $7,317,860.
Amy Schulman is 59, she's been the Independent Director of Alnylam Pharmaceuticals Inc since 2014. There are 11 older and 9 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.
Amy's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal, and Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: